CCM
MLTX icon

Camber Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Camber Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-441,000
Closed -$17.2M – 30
2025
Q1 		$17.2M Hold
441,000
– – 0.61% 24
2024
Q4 		$23.9M Hold
441,000
– – 0.55% 28
2024
Q3 		$22.2M Buy
441,000
+86,000
+24% +$4.03M 0.71% 25
2024
Q2 		$15.6M Buy
+355,000
New +$15M 0.43% 30

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Camber Capital Management's MLTX Position: Q2 2025 in Review

Camber Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2025, closing a stake of 441,000 shares — an estimated $17.2M sold.

Camber Capital Management first reported a position in MLTX in Q2 2024 and held it in 4 quarters. The position peaked at $23.9M in Q4 2024. 130 funds tracked by Wall St. Rank hold MLTX as of Q2 2025.

  • Camber Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Camber Capital Management sold 441,000 MoonLake Immunotherapeutics shares in Q2 2025, an estimated $17.2M.
  • Camber Capital Management first reported a position in MoonLake Immunotherapeutics in Q2 2024 and held it in 4 quarters.
  • Camber Capital Management's MoonLake Immunotherapeutics position peaked at $23.9M in Q4 2024.
  • 130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2025.

Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.